Ultragenyx Pharmaceutical RARE Cost Of Sales And Operating Expenses
Cost Of Sales And Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:CostOfSalesAndOperatingExpenses.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's cost of sales and operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's cost of sales and operating expenses?
- Ultragenyx Pharmaceutical (RARE) reported cost of sales and operating expenses of $305M in Q1 2026.
- How has Ultragenyx Pharmaceutical's cost of sales and operating expenses changed year-over-year?
- Ultragenyx Pharmaceutical's cost of sales and operating expenses increased by 8.2% year-over-year, from $282M to $305M.
- What is the long-term trend for Ultragenyx Pharmaceutical's cost of sales and operating expenses?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's cost of sales and operating expenses has grown at a 13.3% compound annual growth rate (CAGR), from $733.14M to $1.21B.
- What does cost of sales and operating expenses mean?
- This metric aggregates all direct costs of production with broader operating expenditures, including research and development, and selling, general, and administrative costs. It provides a comprehensive view of the total cash and non-cash outflows required to sustain the company's core business operations. Analyzing this total helps evaluate the overall burn rate and operational scale of the enterprise.